Smith Hayes Advisers’s Novartis NVS Stock Holding History

Smith Hayes Advisers’s Portfolio NVS Stock Details NVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	$331K	Buy	5,107 +1,556	+44%	+$106K	0.07%	241
2015 Q4	$274K	Buy	3,551 +52	+1%	+$4.13K	0.06%	264
2015 Q3	$288K	Sell	3,499 -387	-10%	-$34.4K	0.06%	245
2015 Q2	$342K	Buy	3,886 +290	+8%	+$26.6K	0.07%	239
2015 Q1	$318K	Hold	3,596	–	–	0.06%	251
2014 Q4	$299K	Hold	3,596	–	–	0.06%	245
2014 Q3	$303K	Hold	3,596	–	–	0.07%	236
2014 Q2	$292K	Sell	3,596 -291	-7%	-$22.9K	0.07%	236
2014 Q1	$296K	Buy	3,887 +61	+2%	+$4.45K	0.07%	224
2013 Q4	$276K	Buy	3,826 +90	+2%	+$6.26K	0.09%	206
2013 Q3	$257K	Sell	3,736 -333	-8%	-$22K	0.1%	201
2013 Q2	$258K	Buy	+4,069	New	+$265K	0.11%	194

Other funds holding NVS

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BBHC

Brown Brothers Harriman & Co New York $18.6B AUM 15.81% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Institutional Capital Chicago, Illinois $6.75B AUM 3.44% 1-Year Est. Return

Smith Hayes Advisers's NVS Position: Q1 2016 in Review

Smith Hayes Advisers increased its Novartis (NVS) stake by 44% in Q1 2016, buying an estimated $106K and bringing the position to 5,107 shares worth $331K. The position accounts for 0.07% of the portfolio, ranked #241.

Smith Hayes Advisers first reported a position in NVS in Q2 2013 and has held it in 12 quarters since. The position peaked at $342K in Q2 2015. 875 funds tracked by Wall St. Rank hold NVS as of Q1 2016.

Smith Hayes Advisers held 5,107 shares of Novartis worth $331K as of Q1 2016.
Smith Hayes Advisers bought 1,556 Novartis shares in Q1 2016, an estimated $106K.
Novartis made up 0.07% of Smith Hayes Advisers's portfolio in Q1 2016, its #241 holding.
Smith Hayes Advisers first reported a position in Novartis in Q2 2013 and has held it in 12 quarters since.
Smith Hayes Advisers's Novartis position peaked at $342K in Q2 2015.
875 funds tracked by Wall St. Rank held Novartis as of Q1 2016.

Based on Smith Hayes Advisers's 13F filing for Q1 2016, filed 16 May 2016.